Results 211 to 220 of about 120,744 (362)
Vascular Access Management in Inpatients Based on the Vessel Health and Preservation Model
Introduction: Maintaining vascular access is a complex process that involves various clinical factors, the competence of healthcare staff—particularly nurses—and the products used in treatment.
Marisa Manik +9 more
doaj
This study demonstrates that Mn2⁺–tumor DNA complexes encapsulated in dendritic cell (DC)– derived immunogenic extracellular vesicles (EVDC@Mn‐DNA) act as a DC‐specific cGAS– STING activator. EVDC@Mn‐DNA treatment enhances intratumoral DC activation, improves tumor vascular function, promotes CD8⁺ T cell activity, and suppresses pancreatic tumor growth,
Xue Jiang +13 more
wiley +1 more source
Continuous Intravenous Saline Infusion [PDF]
H, Bailey, W I, Stringer, K D, Keele
openaire +2 more sources
Comparison of Endostar continuous versus intermittent intravenous infusion in combination with first‐line chemotherapy in patients with advanced non‐small cell lung cancer [PDF]
Yuan Cheng +5 more
openalex +1 more source
This study identifies Rubicon as a key platelet protein that bidirectionally regulates GPVI and integrin αIIbβ3 signaling. Platelet Rubicon protects against cerebral ischemia‐reperfusion injury by limiting infarction without increasing hemorrhage.
Xiaoyan Chen +11 more
wiley +1 more source
A Phase 1 study of intravenous infusions of tigecycline in patients with acute myeloid leukemia. [PDF]
Reed GA +14 more
europepmc +1 more source
TRPA1+αCGRP+ sensory neurons in the nodose ganglion detect external insults such as lipopolysaccharide (LPS) and interact directly with pulmonary neuroendocrine cells (PNECs), promoting their activation and proliferation. This neural‐epithelial interaction amplifies lung inflammation.
Jie Chen +16 more
wiley +1 more source
PD‐1 Inhibits CD4+ TRM‐Mediated cDC1 Mobilization via Suppressing JAML in Human NSCLC
CD4+ tissue‐resident memory T cells (TRMs) in non‐small cell lung cancer recruit conventional type 1 dendritic cells via XCL1‐XCR1 signaling, orchestrating antitumor immunity. The costimulatory molecule JAML is essential for this process. PD‐1 blockade restores JAML expression and cDC1 mobilization, while JAML agonists synergize with anti‐PD‐1 therapy,
Zheyu Shao +16 more
wiley +1 more source

